Palliative Care
Study register · detail Prospektive Beobachtungsstudie · Palliative Care · 2013

The Medical Necessity for Medicinal Cannabis: Prospective, Observational Study Evaluating

Clear benefit GRADE Low 82 citations
Samplen = 131 Pat.
Duration6-8 weeks
EndpointCTCAE symptom scales
Blindingn.a.
DesignProspektive Beobachtungsstudie
Cannabinoidvollspektrum
Key finding

All cancer- and treatment-associated symptoms showed significant improvement (P < 0.001), with the exception of memory deterioration with prolonged use.

Summary

Prospective observational study in n=131 cancer patients with cannabis license (of initially 211); all cancer- or therapy-associated symptoms showed significant improvement (p<0.001). Only significant side effect: memory impairment with prolonged use (p=0.002). No control group.

P
PopulationCancer patients with medical cannabis license, n=211 (first interview), n=131 (second interview)
I
InterventionMedical cannabis (plant extract), license-based use, form of application not specified
O
OutcomeSignificant improvement of all cancer-related symptoms (p<0,001); only significant side effect: memory impairment with prolonged use (p=0,002)
Confidence in the evidence
Low

The second of four GRADE levels, the effect estimate is of limited reliability.

Quality profile
Sample size
Blinding
Effect size Clear benefit
Citations / year
Authors
Bar-Sela G, Vorobeichik M, Drawsheh S, Omer A, Goldberg V, Muller E
DOI 10.1155/2013/510392
Design: Prospektive Beobachtungsstudie
Share
Abstract
Background. Cancer patients using cannabis report better influence from the plant extract than from synthetic products. However, almost all the research conducted to date has been performed with synthetic products. We followed patients with a medicinal cannabis license to evaluate the advantages and side effects of using cannabis by cancer patients. Methods. The study included two interviews based on questionnaires regarding symptoms and side effects, the first held on the day the license was issued and the second 6-8 weeks later. Cancer symptoms and cannabis side effects were documented on scales from 0 to 4 following the CTCAE. The distress thermometer was used also. Results. Of the 211 patients who had a first interview, only 131 had the second interview, 25 of whom stopped treatment after less than a week. All cancer or anticancer treatment-related symptoms showed significant improvement (P < 0.001). No significant side effects except for memory lessening in patients with prolonged cannabis use (P = 0.002) were noted. Conclusion. The positive effects of cannabis on various cancer-related symptoms are tempered by reliance on self-reporting for many of the variables. Although studies with a control group are missing, the improvement in symptoms should push the use of cannabis in palliative treatment of oncology patients.

The impediment to action advances action. — Marcus Aurelius